Stay updated on Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.

Latest updates to the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe ClinicalTrials.gov site footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check19 days agoChange DetectedA site-wide NIH notice says federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference0.6%

- Check26 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check33 days agoChange DetectedThe footer revision label updated from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check54 days agoChange DetectedA new revision entry, v3.7.0, has been added to the study record history. The previous entry, v3.6.6, has been removed, updating the record's version history.SummaryDifference0.1%

- Check75 days agoChange DetectedThe Record History page lists a new Revision: v3.6.6, replacing v3.6.5, indicating a software/UI update to the history display.SummaryDifference0.1%

Stay in the know with updates to Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.